Aldeyra Therapeutics
ALDX
121 hedge funds and large institutions have $131M invested in Aldeyra Therapeutics in 2025 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 47 increasing their positions, 32 reducing their positions, and 24 closing their positions.
1,258% more call options, than puts
Call options by funds: $1.4M | Put options by funds: $103K
47% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 32
3% less funds holding
Funds holding: 125 → 121 (-4)
6.48% less ownership
Funds ownership: 63.45% → 56.97% (-6.5%)
17% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 24
42% less capital invested
Capital invested by funds: $226M → $131M (-$94.8M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.8M |
| 2 |
6CM
683 Capital Management
New York
|
+$1.56M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.54M |
| 4 |
KCM
Kingdon Capital Management
New York
|
+$1.43M |
| 5 |
D.E. Shaw & Co
New York
|
+$869K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$13.5M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.17M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$1.41M |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
-$1.16M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$979K |
ALDX Hedge Fund Activity: Q2 2025 in Review
121 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q2 2025, worth a combined $131M — down 42% from $226M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ALDX and 20 opened new positions — a net loss of 4 holders — while 32 trimmed existing stakes and 47 added.
The largest buyer was AQR Capital Management, adding an estimated $2.8M. The largest seller was Perceptive Advisors, cutting an estimated $13.5M.
- 121 institutional investors held Aldeyra Therapeutics (ALDX) as of Q2 2025, down from 125 in Q1 2025.
- Funds reported $131M of Aldeyra Therapeutics stock for Q2 2025, down 42% quarter-over-quarter.
- 20 funds opened new Aldeyra Therapeutics positions in Q2 2025 and 24 closed out, a net change of -4 holders.
- The largest Aldeyra Therapeutics buyer in Q2 2025 was AQR Capital Management, an estimated $2.8M added.
- The largest Aldeyra Therapeutics seller in Q2 2025 was Perceptive Advisors, an estimated $13.5M sold.
Based on aggregated 13F filings for Q2 2025.